IL-1ra/IL-1F3/IL1RN Antibody (10309) [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: B/N, ELISA(Cap), ELISA(Det)
• Clone: 10309
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 350

IL-1ra/IL-1F3/IL1RN Antibody (10309) [Alexa Fluor® 350] Summary

• Immunogen: E. coli-derived recombinant human IL‑1ra/IL-1F3
  Arg26-Glu177
  Accession # P18510
• Specificity: Detects human IL‑1ra/IL-1F3 in ELISAs. In ELISAs, this antibody shows less than 0.2% cross-reactivity with recombinant mouse (rm) IL‑1ra and no cross-reactivity with rhIL‑1 alpha , rpIL‑1 alpha , rmIL‑1 alpha , rrIL‑1 alpha , rhIL‑1 beta , rpIL‑1 beta , rmIL‑1 beta , rrIL‑1 beta , rhIL‑1 RI, o
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair)
  • ELISA Detection (Matched Antibody Pair)
  • Neutralization

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-1ra/IL-1F3/IL1RN Antibody (10309) [Alexa Fluor® 350]

• DIRA
• ICIL-1ra
• IL1F3
• IL-1F3
• IL1ra
• IL-1ra
• IL-1ra3
• IL1RN
• IL-1RN
• interleukin 1 receptor antagonist
• IRAP
• MVCD4

Background

IL-1ra was originally isolated from the urine of patients with monocytic leukemia and has also been purified from adherent monocytes. The naturally occurring, fully glycosylated form has an apparent molecular weight of about 25,000 Daltons. The protein shows 26% amino acid homology to IL-1 beta and 19% homology to IL-1 alpha . It will compete with either factor for receptor binding, but does not interact with either one. Human IL-1ra will bind to both types of IL-1 receptor (I and II) on human cells, but reportedly will not block binding to the type II receptor on murine pre-B cell lines. The recombinant, non-glycosylated form of IL-1ra blocks binding of IL-1 to its receptor equally as well as the naturally-occurring, glycosylated form. The IL-1ra has been shown to block the inflammatory responses induced by IL-1 both in vitro and in vivo. Currently, pre-clinical and clinical studies are underway to test possible therapeutic applications for IL-1ra in the treatment of sepsis, rheumatoid arthritis and chronic myelogenous leukemia.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.